Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for mo...

Descripción completa

Detalles Bibliográficos
Autores principales: BOESJES, Celeste M., VAN DER GANG, Liana F., ZUITHOFF, Nicolaas P. A., BAKKER, Daphne S., SPEKHORST, Lotte S., HAECK, Inge, KAMSTEEG, Marijke, de GRAAF, Marlies, DE BRUIN-WELLER, Marjolein S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949218/
https://www.ncbi.nlm.nih.gov/pubmed/36794894
http://dx.doi.org/10.2340/actadv.v103.5243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949218/
https://www.ncbi.nlm.nih.gov/pubmed/36794894
http://dx.doi.org/10.2340/actadv.v103.5243

Ejemplares similares